- Home
- AGIO vs HG Comparison
AGIO vs HG Comparison
Compare AGIO & HG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- HG
- Stock Information
- Founded
- AGIO 2007
- HG 2013
- Country
- AGIO United States
- HG Bermuda
- Employees
- AGIO N/A
- HG N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- HG
- Sector
- AGIO Health Care
- HG
- Exchange
- AGIO Nasdaq
- HG Nasdaq
- Market Cap
- AGIO 2.4B
- HG 2.5B
- IPO Year
- AGIO 2013
- HG 2023
- Fundamental
- Price
- AGIO $40.16
- HG $25.69
- Analyst Decision
- AGIO Strong Buy
- HG Buy
- Analyst Count
- AGIO 4
- HG 7
- Target Price
- AGIO $59.33
- HG $28.29
- AVG Volume (30 Days)
- AGIO 567.8K
- HG 348.1K
- Earning Date
- AGIO 10-30-2025
- HG 11-04-2025
- Dividend Yield
- AGIO N/A
- HG N/A
- EPS Growth
- AGIO N/A
- HG N/A
- EPS
- AGIO N/A
- HG 4.19
- Revenue
- AGIO $44,791,000.00
- HG $2,745,461,000.00
- Revenue This Year
- AGIO $25.57
- HG $21.94
- Revenue Next Year
- AGIO $153.24
- HG $2.99
- P/E Ratio
- AGIO N/A
- HG $6.14
- Revenue Growth
- AGIO 36.26
- HG 21.12
- 52 Week Low
- AGIO $23.42
- HG $16.80
- 52 Week High
- AGIO $62.58
- HG $26.44
- Technical
- Relative Strength Index (RSI)
- AGIO 45.66
- HG 62.14
- Support Level
- AGIO $38.90
- HG $22.66
- Resistance Level
- AGIO $44.10
- HG $26.44
- Average True Range (ATR)
- AGIO 1.72
- HG 0.70
- MACD
- AGIO -0.44
- HG 0.12
- Stochastic Oscillator
- AGIO 24.58
- HG 78.94
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.